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Amniotic fluid stem cell-derived 
vesicles protect from VEGF-induced 
endothelial damage
S. Sedrakyan1, V. Villani1, S. Da Sacco1, N. Tripuraneni1, S. Porta2, A. Achena1, M. Lavarreda-
Pearce1, A. Petrosyan1, H. Soloyan1, R. E. De Filippo1, B. Bussolati2 & L. Perin1
Injection of amniotic fluid stem cells (AFSC) delays the course of progression of renal fibrosis in animals 
with Alport Syndrome, enhancing kidney function and improving survival. The mechanisms responsible 
for these protective outcomes are still largely unknown. Here, we showed that vascular endothelial 
growth factor (VEGF) signaling within the glomeruli of Alport mice is strongly elevated early on in the 
disease, causing glomerular endothelial cell damage. Intraventricular injected AFSC that homed within 
the glomeruli showed strong modulation of the VEGF activity, particularly in glomerular endothelial 
cells. To investigate this phenomenon we hypothesized that extracellular vesicles (EVs) produced by 
the AFSC could be responsible for the observed renoprotection. AFSC derived EVs presented exosomal 
and stem cell markers on their surface membrane, including VEGFR1 and VEGFR2. EVs were able 
to modulate VEGF in glomerular endothelial cells by effectively trapping the excess VEGF through 
VEGFR1-binding preventing cellular damage. In contrast, VEGFR1/sVEGFR1 knockout EVs failed to 
show similar protection, thus indicating that VEGF trapping is a potentially viable mechanism for 
AFSC-EV mediated renoprotection. Taken together, our findings establish that EVs secreted by AFSC 
could target a specific signaling pathway within the glomerulus, thus representing a new potential 
glomerulus-specific targeted intervention.
The complex local autocrine/paracrine signaling between podocytes and glomerular endothelial cells (GEC) is of 
critical importance for the homeostatic balance of the filtration barrier1. In particular, podocytes secrete various 
factors that act directly on the glomerular endothelium2,3. In recent years multiple studies have demonstrated that 
VEGF signaling plays a key role in the development and maintenance of glomerular capillary network and endothe-
lial permeability4,5. An angiogenic imbalance between VEGF (specifically VEGF-A), VEGF receptor 2 (VEGFR2) 
and the soluble vascular endothelial growth factor receptor 1 (sVEGFR1, a truncated variant of the VEGF receptor 
1, VEGFR1) has been reported in many diseases, including kidney disease where modulation of VEGF signaling 
correlates with impaired endothelial fenestrations, endothelial dysfunction and increased proteinuria5–9. Although 
the therapeutic use of compounds with anti-VEGF activity may prevent proteinuria in endothelial murine models of 
diabetic nephropathy10,11, the significance of VEGF/VEGFRs/sVEGFR1 modulation within the glomerular milieu, 
its contribution to GEC damage and progression of chronic kidney disease (CKD) is still not clearly understood.
We previously demonstrated that stem cells derived from amniotic fluid (AFSC) are renoprotective and sig-
nificantly delayed disease progression in a mouse model of Alport Syndrome (AS, where a mutation in any of 
the collIVα3,α4,α5 genes results in the disruption of the glomerular basement membrane (GBM), podocyte 
effacement and renal failure) via preservation of podocyte number and maintenance of glomerular function12. 
The renoprotection by AFSC could possibly be ascribed to their ability to secrete various trophic mediators able 
to stimulate endogenous glomerular repair mechanisms. In this context, stem cell-derived extracellular vesicles 
(EVs), which are important cell-to-cell communication vehicles13, are suggested to be involved in tissue pro-
tective mechanisms14,15. At present, the mechanism(s) responsible for the therapeutic effect of AFSC on GEC 
damage and in particular their possible modulation of the VEGF pathway within the glomerulus has not yet been 
investigated.
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In the present study, we found changes in VEGF signaling activity within the Alport glomeruli, particularly 
during the initiation phase of the disease. Injected AFSC that lodged within glomerular capillaries modulated 
VEGF/sVEGFR1 levels, thus preventing further endothelial damage, possibly by activating endogenous repair 
mechanisms. Specifically, we confirmed that AFSC release EVs that express various surface markers, includ-
ing VEGFR1 and VEGFR2, and can modulate VEGF/VEGFRs signaling in damaged GEC by decreasing the 
bio-availability of excess VEGF. In conclusion, our data confirm the ability of AFSC to ameliorate renal damage 
and establish that their secreted EVs could target a specific signaling pathway re-establishing GEC function, thus 
representing a potentially new glomerulus-specific targeted intervention.
Results
VEGF/VEGFRs/sVEGFR1 signaling characterization within Alport glomerulus. To investigate the 
role of VEGF in AS progression, we determined if VEGF signaling is altered within the glomeruli of Alport mice. 
The specific VEGF isoform we studied is the VEGF-A.
As shown in Fig. 1A–C, VEGF expression, mainly produced by podocytes [Suppl. Figure 1A–H], was markedly 
altered early on in disease and peaked at 3 months but returned to baseline level thereafter. VEGF over-activation 
was shown by the increased pVEGFR2/VEGFR2 ratio in AS glomeruli [Fig. 1D]. At 3 months of age VEGFR1 
expression [Fig. 1E], and the VEGFR1/VEGFR2 ratio were significantly decreased in AS [Fig. 1F]. In addition, 
sVEGFR1 was significantly decreased in later stages (5–6 months of age) [Fig. 1G]. Of note, at 6 months of age, 
no major shifts in the VEGFR1 and VEGFR2 expression were detected between WT and AS glomeruli [Suppl. 
Figure 1I–K] likely indicating that glomerular cells might be counter-reacting to the VEGF signaling alteration at 
this advanced stage of AS by turning down the sensitivity to the signal.
GEC characterization in Alport mice. We next examined the impact of VEGF modulation on GEC. TEM 
scans showed characteristic splitting of the GBM consistent with AS pathology, whereas WT mice had normal 
Figure 1. Evaluation of VEGF, pVEGFR2, VEGFR1 and sVEGFR1 expression within Alport glomeruli 
during disease progression. Changes in VEGF signaling activity were evaluated in glomeruli isolated from 
kidneys of WT and Alport mice over the course of disease progression from 1 to 6 months of age by ELISA, 
immunohistochemistry and Western Blot. As shown in the graph (A), glomerular VEGF, measured by ELISA, 
increased gradually during the early phase of disease peaking at 3 months as compared to time-matched 
siblings, and dropped thereafter (n = 4 WT mice/time point and n = 4 AS mice/time point). Representative 
VEGF staining at 3 months confirmed the presence of elevated VEGF expression (green) in Alport glomeruli 
(B, 40x) as compared against WT controls (C, 40x). Nuclear staining with DAPI (blue). Graphs representing 
immunoblot data of pVEGFR2/VEGFR2 ratio (D, 230 kDa/150 kDa), VEGFR1 expression (E, 151 kDa) and 
VEGFR1/VEFR2 ratio (F) in glomeruli of Alport mice (n = 3 AS mice) compared to their WT littermates 
(n = 3 WT mice) at 3 months of age. Imbalanced expression of VEGF signaling is confirmed by the increase of 
pVEGFR2/VEGFR2 ratio and decrease of VEGFR1 expression. Immunoblots were quantified by densitometry. 
All VEGFR1, VEGFR2 and pVEGFR2 measurements were normalized against corresponding housekeeping 
gene, β-actin, 42 kDa; pVEGFR2/VEGFR2 ratio was assessed after β-actin normalization. Glomerular 
sVEGFR1 expression measured by ELISA decreased in advanced Alport glomeruli (n = 4 AS mice/time point) 
as compared to time-matched siblings (n = 4 WT mice/time point) (G). Two-tail student t-test was used to 
determine differences between WT and AS mice. All values in (A) and (G) are presented as mean ± SEM. All 
scatter plot values are presented as mean ± SD; (*p < 0.05).
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basement membrane thickness [Fig. 2A,C, arrows]. In addition, GEC presented an altered morphology char-
acterized by disruption of fenestrations when compared to WT [Fig. 2A–D, arrowheads] at 3 months of age. 
Fenestration size was significantly increased in Alport mice further confirming changes in GEC morphology 
[Fig. 2B,D,E] during VEGF peak expression. In addition, AS glomeruli showed de novo expression of plasma-
lemma vesicle associated protein-1 (PV1, which plays a key role in diaphragm formation in fenestrae and mainte-
nance of endothelial integrity16,17, [Fig. 2F–K,R]) and alteration of the glycocalyx as shown by downregulation of 
the wheat germ agglutinin (WGA) expression [Fig. 2L–Q,S] during the VEGF peak18,19.
To specifically study the correlation between VEGF modulation and GEC damage, we generated an Alport 
mouse with fluorescently labeled GEC (Alport-TektdT), among other endothelial cells in other organs. We con-
firmed that glomeruli from WT-TektdT mice present with a strong tdTomato (tdT) signal (in red) in GEC [Suppl. 
Figure 2A–E, Fig. 3A,B]. Of note, we identified two distinct populations of tdT positive cells within the glomeru-
lus, represented with bright and dim tdT expression [Suppl. Figure 2E,J,K]. The FACS sorted bright tdT-GEC cells 
were further confirmed for their endothelial phenotype for expression of CD31 by RT-PCR [Suppl. Figure 2F] 
for VE-Cadherin by flow cytometry [Suppl. Figure 3B] and for CD31 and Tie-2 by immunostaining [Suppl. 
Figure 3C]. The tdT-GEC were negative for markers like PDGFRβ, WT1 and Nephrin [Suppl. Figures 2G,H and 
3A,D,E]; thus indicating that within the glomerulus, the tdT is expressed exclusively in GEC, allowing us to 
isolate GEC free from contamination of other glomerular cells. The dim population lacked strong expression 
of endothelial markers [Suppl. Figure 2I]. Therefore for the purpose of this study, we used the former in all the 
experiments described.
Isolated GEC from Alport-TektdT presented altered expression of VEGF signaling, including pAKT and pERK 
(downstream of VEGFR2). The levels of these downstream markers varied largely along disease progression with 
values close to normal at 2 months of age and almost absent at 4 months of age [Fig. 3C,D]; no significant vari-
ation in VEGFR1 expression was detected [Fig. 3E,F]. These variations of the VEGF signaling in GEC present a 
trend similar to that observed within the glomeruli specifically in relation to the turning down of the signaling 
after the VEGF peak. Functionally, these variations correspond to the onset of serum creatinine and proteinuria 
in AS mice as shown in Fig. 4I,J.
Figure 2. GEC damage in Alport mice. Alport mice showed GEC damage during early stage of disease (A–S). 
Representative transmission electron microscopy images showing characteristic thickening and splitting of 
the GBM in Alport mice (arrow, A, 28,000x), enlarged endothelial fenestrations and ruptured endothelial layer 
(arrowheads, A–B, 28,000x) when compared to their littermate WT mice (C–D, 28,000x). GEC fenestrations 
were enlarged in Alport mice (n = 3 AS mice) at 3 months of age when compared to the WT mice (n = 3 WT 
mice) as shown by the graph in E. Fenestration size was measured by ImageJ in 20 TEM images per sample. 
Values are presented as mean ± SEM. Representative confocal immunofluorescence images of AS glomeruli 
showing altered PV1 (green, F–H, 63X) and WGA (red, L–N, 63X) expression compared to WT glomeruli 
(I–K, O–Q, 63X) at 3 months of age (n = 3 AS mice and n = 3 WT mice). Of note, PV1 staining is present in 
peritubular capillaries that unlike GEC express normal level of PV1 under physiological conditions. Nuclear 
staining with DAPI (blue). Graphs representing morphometric quantification of the PV1 (R) and WGA staining 
(S) in AS and WT glomeruli. Measurements were performed by ImageJ software (NIH) and each dot represents 
the median value of 20 images per mouse. Two-tail student t-test was used to determine differences between 
WT and AS mice, (*p < 0.05, **p < 0.01). All scatter plot values are presented as mean ± SD; (*p < 0.05).
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AFSC effects on intraglomerular regulation of VEGF signaling and on GEC biology. To study the 
modulation of VEGF signaling by AFSC, mice were treated with a single injection of CM-DiI or Q-Dot tagged 
AFSC (the same cell line as published12) prior to the onset of a high level of proteinuria [Suppl. Figure 4A,B]. 
AFSC localized predominantly within the kidney, specifically in glomeruli [Fig. 4A–C and Suppl. Figure 4C,D] in 
close association with GEC as shown by a co-staining with VE-cadherin (endothelial cells) and CD2AP (podo-
cytes) [Suppl. Figure 4D] after 5 days of delivery. Cells were not found in other organs in any significant number 
[Suppl. Figure 4E,F], as previously reported12. After 2 weeks of AFSC injection, the pVEGFR2/VEGFR2 ratio and 
VEGFR1 expression within the isolated glomeruli was comparable with that of the WT [Fig. 4D,E]. Although 
no significant changes in the VEGFR1/VEGFR2 ratio was observed between AFSC treated and non-treated ani-
mals, AFSC were able to significantly reduce VEGFR2 phosphorylation when total VEGFR2 expression remained 
unchanged [Fig. 4D]. After 7 weeks of injection, VEGF level was unchanged and sVEGFR1 expression was 
Figure 3. VEGF signaling is altered in GEC isolated from Alport mice. VEGF signaling changes in GEC were 
studied using tdTomato-labeled GEC (tdT GEC) isolated by FACS from Alport-TektdT glomeruli (A, 10x). 
tdT signal (red) is strongly present in all cells as shown in (B) (10x, two passages in culture) (n = 3). Graphs 
representing immunoblot data of pAKT/AKT (C, 60 kDa/60 kDa), pERK/ERK (D, 42 kDa/42 kDa), VEGFR1 
expression (E, 151 kDa) in glomeruli of tdT GEC derived from WT mice and Alport-TektdT mice at different 
ages. Imbalanced VEGF signaling is evident during disease progression in GEC, identified by a strong alteration 
in pAKT/AKT and pERK/ERK signaling downstream of VEGFR2. (F) Immunoblots of all the experimental 
groups used to generate the graphs presented in Figures C–E. Immunoblots were quantified by densitometry 
(VEGFR1 measurements were normalized against corresponding housekeeping gene, β-actin, 42 kDa). These 
data were obtained using GEC derived from n = 4 WT at 5 months of age, n = 4 AS mice at 2 months of age, 
n = 6 AS mice at 3 month of age, n = 4 AS mice at 6 months of age. One-way ANOVA with Tukey’s post hoc test 
was used to analyze the data and scatter plot values are presented as mean ± SD (*p < 0.05).
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elevated and was comparable with that of the WT [Fig. 4G,H], followed by mitigation of serum creatinine and 
proteinuria in treated mice [Fig. 4I,J]. To verify that AFSC can mitigate GEC damage, we performed co-culture 
assays between AFSC and GEC (with no cell-cell contact) overexposed to VEGF for 24 h. Exposure to VEGF at 
100ng/ml caused increased expression of VEGF, pVEGFR2 in GEC [Suppl. Figure 5A,B]. After 24 hr of VEGF 
exposure, GEC demonstrated changes in expression pattern of VE-cadherin and CD31 [Suppl. Figure 5C–F] and 
decreased cellular proliferation that was rescued by AFSC [Suppl. Figure 5G–J]. AFSC co-culture normalized 
increased expression of genes like VEGF, fibronectin, and Ccl5 [Suppl. Figure 5K], thus protecting GEC from 
VEGF-induced damage.
Figure 4. AFSC homing to the kidney and modulation of VEGF, pVEGFR2, VEGFR1 and sVEGFR1. Alport 
mice were injected at 3 months of age to study homing of AFSC and modulation of VEGF signaling. Injected 
labeled-AFSC (CM-DiI, red) were traceable after 5 days and could be detected by fluorescence within Alport 
glomeruli (A, 20x). Representative image of isolated glomeruli from Alport mice after 5 days of injection 
showing CM-DiI labeled AFSC in red (B, 10x; C, higher magnification 40x). Injection of AFSC modulated 
expression of pVEGFR2/VEGFR2 ratio (D, 230 KDa/150 kDa), VEGFR1 (E, 151 KDa) and VEGFR1/VEGFR2 
ratio (F) within the glomeruli of Alport mice (n = 3 AS mice) compared to non-injected siblings (n = 3 AS 
mice) after 2 weeks of injection, restoring the activity of these VEGFRs almost at normal levels. Immunoblots 
were quantified by densitometry (VEGFR1, VEGFR2 and pVEGFR2 measurements were normalized against 
corresponding housekeeping gene, β-actin, 42 KDa; pVEGFR2/VEGFR2 ratio was assessed after β-actin 
normalization). As shown in graph G–H, injection of AFSC modulated levels of VEGF and sVEGFR1 as 
measured by ELISA in Alport (n = 3 AS mice) versus non-treated mice (n = 3 AS mice) at 7 weeks after 
injection. Injection of AFSC also ameliorated serum creatinine (I) and proteinuria (J) in Alport mice (n = 6) 
compared to non-treated Alport mice (n = 6) and WT (n = 5) measured over 12 weeks period after AFSC 
injection. #Significant difference between WT and AS+AFSC; †Significant difference between WT and AS. 
*Significant difference between AS and AS+AFSC. One-way ANOVA with Tukey’s post hoc test was used to 
analyze the data in Fig. (D–H); Two-way ANOVA with Tukey’s post hoc test was used to analyze the data in 
Fig. (I,J); values in (I) and (J) are presented as mean ± SEM. All scatter plot values are presented as mean ± SD; 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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Characterization of AFSC-derived EVs. Since EVs have been established as an important mechanism of 
cell-to-cell communication13–15 we hypothesized that secretion of EVs from AFSC could be one of their mecha-
nisms of action. In order to test our hypothesis, EVs from culture supernatants of AFSC were isolated by sequen-
tial ultracentrifugation. By Nanosight analysis, EVs were characterized as a heterogeneous population ranging 
from 100 nm to 400 nm in size, and their production in basal culture conditions appeared as roughly 2 × 1010 
EVs released by million cells in 24 hours [Fig. 5A]. AFSC-derived EVs expressed surface markers typical of the 
cell of origin (CD73 and CD29) and CD24, a marker of amniotic fluid-derived exosomes20 [Fig. 5B,C]. EVs also 
expressed VEGFR1 and VEGFR2 [Fig. 5B,C] but did not contain VEGF [Fig. 5D]. EVs contained miRNAs that 
specifically modulate VEGF/VEGFRs signaling21 including miR-16.1, miR-23a, miR-27a, miR-93, miR-221, miR-
145 and miR-322 [Suppl. Figure 6A].
To demonstrate that AFSC-derived EVs can be transferred to GEC, AFSC were transduced with LentiBrite 
GFP packaged lentiviral particles to constitutively express GFP and additionally tagged with CM-DiI. After over-
night incubation with GECs, red/green EVs were found within the cytoplasm of GEC in proximity to the perinu-
clear zone [Suppl. Figure 6B–I].
AFSC-derived EVs contribute to VEGF signaling modulation in GEC. To demonstrate EV ability 
to modulate VEGF activity and confirm the potential role of VEGFR1 and sVEGFR1 in GEC damage/repair 
processes we generated knockout (KO) EVs for Flt1, EVFlt1−/−, (Flt1 gene codifies for both the VEGFR1 and 
sVEGFR1) by transfecting AFSC using a shRNA Lentiviral Particles Transduction system. The clone with the 
highest efficiency of transduction was used to derive and collect EVFlt1−/−. Both, KO AFSC and derived EVs 
showed reduced VEGFR1 expression [Fig. 6A–D]. After generation of the EVFlt1−/− we exposed GEC to VEGF and 
treated them with normal EVs, KO EVs and neutralizing VEGF antibody (used as a positive control). pVEGFR2/
VEGFR2 ratio and VEGFR1 expression were restored to baseline in the presence of EVs [Fig. 6E,G,I,K] but not 
with KO EVs, thus confirming that sVEGFR1 plays a role in regulating VEGFR1 expression and VEGFR2 activity. 
Importantly, EVs seem to have more efficiently downregulated VEGFR2 phosphorylation when compared with 
neutralizing antibody [Fig. 6E,F], and they both showed a similar effect when assessed against total VEGFR2 
[Fig. 6G,H]. Interestingly, EVs but not anti-VEGF neutralizing antibody downregulated VEGFR1 expression in 
Figure 5. AFSC-EV characterization. (A) Graph representing Nanosight analysis of AFSC-derived EVs. 
The mean size and particle concentration are calculated by the Nanoparticle Tracking Analysis software. 
(B) FACS analyses of AFSC-derived EVs showing the expression of mesenchymal (CD29, CD44, CD73, 
CD90, CD105 and CD146), exosomal (CD9, CD24 and CD63) and angiogenic related (CD202b, VEGFR1, 
VEGFR2, Neuropilin-I and Neuropilin-II) surface markers. EVs were derived from the same cell line and the 
FACS analysis was repeated in quadruplicate. Dot lines indicate the isotopic controls, filled area the specific 
antibodies. (C) Representative FACS graphs related to figure (B). (D) Representative Western Blotting showing 
absence of VEGF (43 KDa, dimer) within AFSC-derived EVs compared to GEC used as control. Values are 
presented as mean ± SEM.
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GEC [Fig. 6I,J]. We speculate that EVs might present multiple mechanisms of action (due to their cargo) that are 
lacking in the control antibody experiment. Of note, slight differences in VEGFR1 level between in vitro and in 
vivo data can be attributed to the fact that in vivo data shows expression of all the glomerular cell types, including 
GEC, whereas in vitro data only reflects GEC response.
Interestingly, GEC exposed to EVs showed a greater retention of VEGF within the media [Fig. 7A] com-
pared to GEC exposed to KO EV. These data suggest that EVs (that do not contain VEGF as reported above) 
could trap excess VEGF contained in the media, thus preventing its binding to VEGFRs on GEC and inter-
nalization subsequently regulating VEGFR2 and VEGFR1 activity. To prove our hypothesis we performed a 
co-immunoprecipitation assay, using anti-VEGFR1 antibody to pull down VEGFR1 on the same culture media 
and probed for VEGF. Indeed, Fig. 7B shows a lower level of VEGF in the experimental group with KO EVs 
Figure 6. Generation of AFSC/EVFlt1−/− and VEGFR2 and VEGFR1 modulation by AFSC-EVs in GEC. (A) 
Different viable clones obtained from AFSC transduced with Flt1 shRNA lentiviral particles where analyzed 
by qPCR for Flt1 expression after puromycin selection. AFSC were transduced with different titrations of viral 
particles (5, 10, 20 MOI) to obtain the best transduction efficiency. As shown, resulting puromycin-resistant 
clones have varying levels of Flt1 expression due to the random integration of the lentiviral construct into the 
genome of the cells. Clone A6 (first column) was selected as the most efficient. (B) Relative gene expression of 
Flt1 in non transduced AFSC compared to Flt1 KO AFSC (clone A6) showing 90% reduction. VEGFR1 protein 
(151 KDa) expression was quantified by Western Blot analysis in cell lysates of AFSC and KO AFSC (clone 
A6) (C) and EVs isolated from both cell populations (D) showing respectively 50% and 60% reduction. All 
measurements were normalized against their corresponding housekeeping gene, β-actin, 42 kDa. (E–L) Graphs 
showing differential expression of pVEGFR2 and VEGFR2 (E, 230 KDa and 150 KDa), pVEGFR2/VEGFR2 
ratio (G), VEGFR1 expression (I, 15 KDa) and VEGFR1/VEGFR2 ratio (K) in GEC (basal condition, control), 
GEC stimulated with VEGF (100 ng/ml) and treated with EVs and KO EVs for 24 hr. Expression of pVEGFR2 
and VEGFR2 (F), pVEGFR2/VEGFR2 ratio (H), VEGFR1 expression (J) and VEGFR1/VEGFR2 ratio (L) were 
also evaluated in GEC treated with neutralizing VEGF antibody (used as control). Both pVEGFR2 and VEGFR1 
were restored to basal level in the presence of normal EVs and of the neutralizing VEGF antibody, but not in the 
presence of KO EV. Experiments were repeated in triplicate and Western Blot bands are presented in (M) and 
(N). Immunoblots were quantified by densitometry (VEGFR1, measurements were normalized against their 
corresponding housekeeping gene, β-actin, 42 KDa). One-way ANOVA with Tukey’s post hoc test was used to 
analyze the data between 3 or more groups. All scatter plot values are presented as mean ± SD, (*p < 0.05).
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compared to normal EVs. This data was confirmed independently using a different assay [Fig. 7C], where EVs 
and KO EVs were exposed to VEGF without the presence of GEC. Both these experiments confirmed that EVs 
can trap VEGF through VEGFR1, thus balancing VEGF signaling.
Direct administration of EVs into AS mice at 8 weeks of age and before the onset of a high level of proteinuria 
improved renal physiological parameters, including proteinuria and serum creatinine [Fig. 7D,E]. In particular, 
proteinuria level was significantly ameliorated in treated animals over many weeks as compared to non-treated 
mice [Fig. 7D].
Discussion
Various molecular signaling pathways contribute to the cell-cell communication between podocytes and GEC1,22 
but VEGF expression plays a key role in the maintenance of the structure and function of glomerular capillar-
ies including permeability, while its alteration plays a major role in CKD5. In normal animals, the blockade of 
VEGF correlates with GEC damage and an increase of proteinuria23. On the contrary, in diabetic mice, VEGF is 
upregulated, and its blockade ameliorates diabetic albuminuria24. Therefore, both deficiency and excess of VEGF 
appear to be detrimental to the physiological integrity of glomerular capillaries. An imbalance between VEGF 
and sVEGFR1 has been reported in many diseases, including the kidney6–9, as inducing widespread endothelial 
dysfunction, proteinuria, and hypertension.
Figure 7. VEGF modulation by AFSC-EVs in GEC and AFSC-EV effect on renal function. (A) Graph showing 
level of VEGF (24 KDa, monomer) within the media collected from GEC (basal condition, control), GEC 
stimulated with VEGF (100 ng/ml) and treated with EVs and KO EVs for 24 hr. VEGF level was higher in GEC 
stimulated with normal EVs compared to GEC stimulated with KO EV. Experiments were repeated in triplicate 
and data were quantified (measurements were normalized against VEGF basal level in GEC only group 
since Western Blot was performed in collected media; Western Blot bands are presented below the graph). 
(B) Representative immunoblot of VEGF after co-immunoprecipitation with VEGFR1 on the supernatant 
collected from experimental groups described in (A), showing the inefficiency of the KO EV to trap VEGF 
when compared to that of normal EVs. (C) Representative immunoblot of VEGF, after co-immunoprecipitation 
with VEGFR1 on samples of PBS solution containing high VEGF dose (100ng/ml) and treated with EVs and 
KO EVs for 24 hr further confirming the inability of the KO EV to effectively trap VEGF compared to normal 
EVs. The weak band detected in the PBS/VEGF only group represent a VEGF carryover due to incomplete 
removal of VEGF during the washing steps. Immunoblots were quantified by densitometry. (D) Injection of 
EVs ameliorated proteinuria in Alport mice (n = 8) compared to non-treated Alport mice (n = 8) and WT 
(n = 5) measured over 28 weeks period after EVs injection. (E) EV treatment also improved serum creatinine 
level within the same treated animals. Note: toward the end of the study at 28 weeks few mice were lost due to 
advanced disease. *Significant difference between AS and AS + AFSC. One-way ANOVA with Tukey’s post hoc 
test was used to analyze the data. All scatter plot values are presented as mean ± SD, (*p < 0.05, **p < 0.01, 
***p < 0.001).
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Importantly, accumulation of VEGF in human glomeruli was reported in various kidney diseases25,26, includ-
ing AS27, thus supporting its importance in kidney disease. However, the biological role of VEGFR1/sVEGFR1 
in the context of glomerular endothelial damage and its correlation with increased proteinuria is still unknown. 
Because GEC express an abundance of both VEGFR2 and VEGFR1, it is plausible that VEGFR1 and sVEGFR1 
might have key importance in the regulation of the VEGF signaling activity in these cells.
Indeed, in our CKD animal model, we found that VEGF is elevated particularly early in the disease, reaching 
the maximum expression at 3 months of age, and then decreasing in more advanced stages. Interestingly, the 
level of sVEGFR1 within AS glomeruli also decreased after the peak of VEGF expression, thus possibly indicat-
ing that sVEGFR1 fails to effectively counter-balance the VEGF increase gradually causing glomerular damage. 
In an elegant study, Quaggin’s group28 identified that podocytes produce sVEGFR1 and that its elimination in 
podocytes causes profound cellular damage and increased proteinuria. Since podocytes are the major producers 
of VEGF2,3 within the glomerulus and since sVEGFR1 has autocrine activity on podocytes, a possible explanation 
for decreased VEGF and sVEGFR1 levels with disease progression might be the loss of podocytes during AS 
progression. Indeed, we showed12 that AS glomeruli at 4 months of age have a significantly reduced number of 
podocytes compared to WT at the same age.
Significant changes in VEGFR2 activation and VEGFR1 expression were evident during the initial phase of 
AS progression when podocyte loss is not predominant and proteinuria is still low. These observations strongly 
suggest that in addition to the podocyte, which has been considered as the culprit of CKD progression including 
AS29, the endothelium could also contribute to the initiation and progression of glomerular damage in AS as well 
as potentially in other forms of CKD.
Indeed, GEC damage represented by disruption of fenestration size and glycocalyx structure is very evident 
in 3 months old kidneys. We also confirmed that GEC at this stage present with abnormal activation of AKT and 
ERK, especially during and after the VEGF peak. Therefore, we speculate that in early stages of AS, the elevated 
VEGF activity might be fundamental in promoting GEC damage, thus, in turn, causing podocyte injury and 
proteinuria. Interventions aimed at preventing early endothelial damage, possibly by regulating VEGF expression 
might, therefore, present an alternative pathway to delaying renal disease progression.
We have previously shown that AFSC, when injected before the onset of proteinuria, are able to slow down 
disease progression in AS mice12. Here we demonstrate that AFSC home predominantly within the glomeru-
lus of Alport mice and localize adjacent to the GEC, thus potentially triggering a regulatory response in GEC. 
Thus, AFSC decreased pVEGFR2 and increased VEGFR1 within the glomeruli, confirming that AFSC can mod-
ulate VEGF/VEGFRs activity. We also previously reported that AFSC injection preserves podocyte number12, 
which might account for the normalization of VEGF and sVEGFR1 levels observed in injected mice, as presented 
herein. Preservation of podocyte number and regulation of VEGF and sVEGFR1 expression were also correlated 
with improvement of kidney function.
Due to their close proximity to GEC, we hypothesized that one of the possible mechanisms of renoprotection 
by AFSC could be via EV release. Recent studies have demonstrated that EVs released from cells are an integral 
component of the cell-to-cell communication network involved in tissue regeneration13–15 and therefore may con-
tribute to the paracrine activation of stem cells in renal regeneration, by directly activating target cells to secrete 
functionally active agents30.
Several groups, including us, have already demonstrated the in vivo ability of EVs derived from bone marrow 
mesenchymal stem cells to provide protection from acute kidney injury31–34. Here, we demonstrate that indeed 
AFSC do secrete EVs, which express surface mesenchymal/exosomal markers as well as a number of angiogenic 
receptors, including VEGFRs. Importantly, we demonstrated for the first time that administration of AFSC derived 
EVs can provide a functional benefit, similar to that of injection of AFSC. This effect could be due to EVs function-
ing as a “trap” for excess VEGF by binding to VEGFR1 presented on the EVs surface. We, therefore, speculate that 
modulation of VEGF within the glomeruli involves trapping of VEGF by VEGFR1 on the surface of AFSC-derived 
EVs. In this context, the EVs presenting VEGFR1 on their surface might counterbalance the decrease in sVEGFR1 
observed during AS progression. It is also known that VEGF signaling disruption is a major occurrence in diabetic 
nephropathy, especially during the early phase of the disease5. Therefore, we speculate that EVs might also regulate 
VEGF expression in diabetic nephropathy as well as in other forms of CKD with altered glomerular VEGF sign-
aling. Importantly, despite the higher level of VEGFR2 over VEGFR1 on EVs, the affinity of the VEGF-VEGFR1 
interaction is ten times stronger to that between VEGF-VEGFR235. This mechanism of action could potentially be 
expanded to other molecules (such as TGFβ or ang II), since EVs present many different receptors. Downregulation 
of these molecules through “trapping” could thus be beneficial to resolving glomerular damage.
Recently, it was shown that EVs derived from AFSC contain specific miRNAs as cargo36,37. Indeed, we also 
found that EVs contain miRs known to act in the modulation of VEGF levels (miR-16.1, -93), VEGF receptors 
(miR-16.1), as well as both positive and negative regulators of the VEGF signal transduction cascade (miR-23a, 
-27a, -221, -322 and -145)21. This angiomodulatory cargo could involve potential new mechanisms of VEGF reg-
ulation, by triggering mechanisms of repair/regeneration at the transcriptional level. We focused on the VEGF 
signaling because of its importance in maintenance of the glomerular capillary network. Moreover, the presence 
of a wide variety of surface markers as well as regulatory miRNAs within the EV, likely indicates potential of the 
AFSC-derived EVs to be able to regulate other important mechanisms essential to the glomerular homeostasis, 
and especially to the endothelium (such as the oxidative stress pathway, iNOS, TGF-β, and Ang II). However this 
tantalizing finding requires further investigation and is beyond the scope of the current study.
Although in depth analyses would be required to determine if EVs account for all of the reno-protective effects 
of AFSC, we clearly demonstrated that EVs are capable of changing the course of disease progression in Alport 
mice (as evidenced by the regulation of proteinuria and serum creatinine), similar to that injected with AFSC. 
In conclusion, we demonstrated that 1. VEGF signaling plays an important role in the disruption of glomerular 
homeostasis and that injection of AFSC can restore the activity of this signaling pathway, possibly preventing 
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further loss of kidney function. 2. Alterations in VEGF signaling affect the glomerular endothelium during early 
AS and before massive loss of podocytes and elevated proteinuria. 3. AFSC home within glomeruli in proximity 
to GEC and release “angiomodulatory” EVs. 4. AFSC-derived EVs can modulate VEGF signaling by podocytes 
and other glomerular cells (such as mesangial cells that can contribute to the variation of VEGF during disease 
progression) by trapping excess VEGF thorough VEGFR1-binding.
Since AFSC localize within the glomeruli in our animal model, we speculate that the delivery of EVs by AFSC 
can specifically target VEGF signaling in this key renal compartment, thus favoring a correctly dosed, local ther-
apeutic action of VEGF exactly where it is needed. Potential strategies to modulate glomerular cell crosstalk, 
specifically for preventing initiation and progression of GEC damage will strengthen the rationale for novel ther-
apeutic approaches directed towards homeostatic regulation of glomerular function.
Methods
AFSC culture, GFP infection and Flt1 knockout experiments. Clonal lines of AFSC were derived 
and cultured as previously described12. For GFP transfection, AFSC were seeded at a density of 2.5 × 104/cm2 and 
transduced with LentiBrite GFP packaged lentiviral particles (Millipore, #17-10387) at 35MOI. Transduction 
efficiency was assessed by inverted fluorescence microscope (Leica DMI6000 B). AFSCGFP were selected by FACS 
(BD, FACSAria III) and used for EV isolation.
AFSCFlt1−/− were generated by using a shRNA Lentiviral Particles Transduction system (Santa Cruz 
Biotechnology, #sc-35395-V) following manufacturers’ instructions. Seeded AFSC (10,000/cm2) were transduced 
at 5MOI, and stable clones were selected via puromycin selection (10 ug/ml) for about 2 weeks. The clone with the 
highest KO efficiency was used for collecting EVs.
Animal models (WT mice, Alport mice, WT- Alport-TektdT, Alport-TektdT), AFSC and EV injec-
tions and AFSC in vivo tracking, serum creatinine, and proteinuria measurements. All ani-
mals were purchased from the Jackson Laboratory12. The Alport-TektdT mice were generated by breeding Alport 
mice (B6.Cg-Col4α5tm1Yseg/J) with an endothelial specific Cre-driver mouse (B6.Cg-Tg(Tek-cre)1Ywa/J and 
a tdT-reporter mouse (B6.Cg-Gt(ROSA)26Sortm14(Cag-td-Tomato)Hze/J); these mice express tdTomato (tdT) in all 
endothelial cells including GEC. To study disease progression n = 24 WT and n = 24 Alport mice were sacrificed 
at 1, 2, 3, 4, 5 and 6 months of age (n = 4/time point) to isolate glomeruli. For TEM analysis n = 3 of WT and 
n = 3 of Alport mice were used. For in vivo experiments n = 10 of WT, n = 10 of Alport mice non-injected and 
n = 10 Alport mice injected with AFSC were used. Mice were injected with 1 × 106 AFSC through the left ventri-
cle at 3 months of age, before an onset of proteinuria as published12. Mice were sacrificed at 2 and 7 weeks post 
injections. In addition, Alport mice were injected with the equivalent number of EV (2.0 × 1011) as produced by 
1 × 106 AFSC (n = 8). Non-injected, aged matched Alport mice (n = 8) and WT mice (n = 5) served as control. 5 
WT-TektdT were used for flow cytometry data.
For cell tracking, 6 Alport mice were injected with AFSC pre-labeled with Qdot (or CM-DiI) immediately 
before the procedure (Invitrogen). The animals were killed at 5 days (n = 3), and 10 weeks (n = 3) after treatment, 
and the heart, kidney, liver, and lung were processed for FACS analysis as previously described12. A non-injected 
littermate served as the negative control throughout the analysis for each time point.
Renal function was assessed as previously described12. Of note, we refer to early stage AS when the level 
of proteinuria is <3 g/g (up to 3 months of age), to middle stage AS when proteinuria is ~10-13 g/g (around 4 
months of age) and to late stage AS when proteinuria is >20 g/g (5 months of age and beyond). Experiments were 
performed in adherence to the NIH Guidelines for the Care and Use of Laboratory Animals and with Children’s 
Hospital Los Angeles Institutional Animal Care and Use Committee (IACUC) approval. Total number of mice 
used in experiments is 177: WT mice (n = 57), Alport mice (n = 90), WT-TektdT (n = 13) Alport-TektdT(n = 23).
Glomeruli and GEC isolation. Glomerulus isolation was performed as previously described12 and GEC 
from WT-TektdT (n = 7) and Alport-TektdT (n = 20) were isolated by further digesting the glomeruli with 0.25% 
trypsin (Gibco, ThermoFisher Scientific)/ 0.6% collagenase IV (Worthington) solution in media supplemented 
with phosphatase inhibitors (ThermoFischer Scientific) for 20′ at 37 °C. Cells were then passed through a 100μm 
strainer and GEC were flow sorted using FACSAria III (Becton Dickinson).
EVs isolation, characterization and labeling. EVs were isolated from supernatants of AFSC cultured 
overnight in RPMI-1640 (Lonza) without serum33. Supernatants were centrifuged at 6,000 g for 20′ and ultracen-
trifuged at 100,000 g (Optima L-100K ultracentrifuge; Beckman Coulter) for 2 hours at 4 °C; pellets were resus-
pended in serum-free RPMI-1640 containing 1% DMSO and stored at −80 °C until use. EVs were characterized by 
cytofluorimetric analysis38, using fluorescein isothiocyanate (FITC), phycoerythrin (PE) or allophycocyanin (APC) 
conjugated rat antibodies. AFSC-EVs (1 × 109 particles) were incubated for 15′ at 4 °C and immediately acquired 
by FACS analysis using a Guava easyCyte™ Flow Cytometer (Millipore) and analyzed with InCyte software (See list 
in Supplementary Material and Methods). Fluorochrome conjugated rat non-immune isotypic immunoglobulin G 
(Miltenyi Biotec) was used as a control. The size and distribution of the AFSC-EVs were analyzed using a NanoSight 
LM10 instrument (NanoSight Ltd.) equipped with the nanoparticle tracking analysis (NTA) 2.0 analytic software.
RNA isolated using the mirVana RNA isolation kit (Ambion), was analyzed using miScript Reverse 
Transcription Kit and miScript SYBR Green PCR Kit (both from Qiagen). Fold change in miRNA expression was 
calculated as 2−∆Ct using the snoRNA RNU6b as normalizer38. A quantitative real-time polymerase chain reaction 
(qRT-PCR) was performed using a 96-well StepOne™ Real-Time System (Applied Biosystems) in order to analyze 
the EVs miRNA content. The sequence-specific oligonucleotide primers were all obtained from MWG-Biotech 
(www.mwg-biotech.com, see list in Supplementary Materials and Methods).
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Western Blotting, immunostaining, TEM, GEC quantification, VEGF and sVEGFR1 ELISA, PCR, 
PCR array, flow cytometry. Western blotting, immunostaining, PCR and PCR array, flow cytometry were 
performed as previously published12,39. Details are described in the Supplementary Materials and Methods. TEM 
analysis was performed as published12 and expression for VEGF and sVEGFR1 in glomerular extracts, serum and 
supernatants were assessed by ELISA according to manufacturers’ instructions (RayBiotech, #ELM-VEGF and 
#ELM-VEGFR1). GEC fenestration size was evaluated in 20 randomly selected TEM images per sample (n = 3) 
with a field of view at 28,000x. The surface areas of the fenestrations were quantified by ImageJ software (NIH). 
All measurements were done in a double-blinded fashion.
Alport (n = 3) and WT (n = 3) mice were administered with FITC-WGA lectin (from Triticum vulgaris; 
6.25 mg/kg body wt; Ab20528; Abcam, MA) via an intracardiac injection and sacrificed after 30 minutes. Kidneys 
were snap frozen and 5μm sections were processed for confocal microscopy. Images were taken with Leica Zeiss 
710 microscope and analyzed using the ZEN10 software.
Co-immunoprecipitation assay. To evaluate VEGF/VEGFR1 interactions between VEGFR1 expressed 
by EVs and the excess of VEGF described in the in-vitro experiments, immunoprecipitation for VEGFR1 
using VEGFR1 antibody and Protein G-agarose conjugate (Santa Cruz) was applied overnight at 4 °C. 
Immunoprecipitates were collected by centrifugation at 1,000 × g for 5′ at 4 °C, washed with PBS and resus-
pended in electrophoresis sample buffer, denatured and ran under reducing conditions as previously described12. 
The immunoblots were then probed for VEGF detection using VeriBlot-HRP conjugated secondary antibody 
(Abcam) and standard Western Blotting techniques as previously described12.
In vitro co-culture of GEC-AFSC and GEC-EVs. GEC were seeded at 1 × 104 cells/cm2 at 37 °C and 5% 
CO2 in medium supplemented with 0.1% VEGF, 0.1% ECGS, 0.1% Heparin, 0.1% EGF, 0.1% Hydrocortisone, 
1% L-Glutamine, 1% antibiotic-antimycotic solution, 5% FBS (CellBiologics). GEC were overstimulated with 
recombinant VEGF (Gibco, ThermoFisher Scientific) at 100ng/ml. Simultaneously, AFSC (ration 1:1, on transwell 
inserts, Corning) or EVs and EVFlt1−/− (10,000:1 ratio, on culture media) were co-cultured with GEC under the 
same growth conditions. Experiments were terminated at 24 hours and culture media and cells were collected for 
analysis. Integration of EVs into GEC was performed by applying EVs with green and red fluorescence tags derived 
from AFSCGFP co-labeled with CM-DiI as previously reported12 to GEC overnight. Integration of EV into GEC 
was assessed by inverted fluorescence microscope (Leica DMI6000 B). Experiments were repeated in triplicate.
Statistical analysis. All test populations were assumed to have Gaussian distribution and equal variance. 
Data shown in bar graphs are expressed as means ± SEM. Two-tailed Student’s t-test was used for comparisons 
between two groups. One-way ANOVA with Tukey’s post hoc test was applied for comparison of three or more 
groups for the same time point. Two-way ANOVA with Tukey’s post hoc test was applied for comparison of three 
or more groups between different time points (Fig. 4I,J). All statistical analysis was done with graphPad Prism 
7.0a (GraphPad Software, Inc.). A p-value less than 0.05 was considered statistically significant.
Data availability statement. All data generated or analyzed during this study are included in this pub-
lished article (and its Supplementary Information files).
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